OTTAWA, Jan. 27, 2017 /CNW/ -
Issue
Health Canada is advising Canadians that it has seized three unauthorized workout supplements from Reflex Supplements at #105–10712, 78 Ave., Grande Prairie, AB. "Animal PM" is labelled to contain L-dopa while "Blade" is labelled to contain yohimbine. L-dopa and yohimbine are prescription drugs and can pose serious health risks. "Rich Piana 5% Nutrition – 5150" is labelled to contain a combination of synephrine and caffeine, a combination that can also pose serious health risks. This product was previously recalled by another company for the same reason.
These products may also be sold at other retail locations in Canada.
Who is affected
- Consumers who have bought or used these products.
Affected products
| Affected products |
Labelled to contain |
| Animal PM |
Mucuna Pruriens (seed) (standardized for 15% L-dopa) |
| Blade |
Yohimbine HCL |
| Rich Piana 5% Nutrition - 5150 |
Caffeine and synephrine HCL |
What consumers should do
- Stop using these products. Consult with your health care professional if you have used these products and have health concerns.
- Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit DIN, DIN-HM or NPN. You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
- Report adverse events to health products to Health Canada by calling toll-free at 1‑866‑234‑2345, or by reporting online, by mail or by fax.
- Report complaints about health products to Health Canada by calling toll-free at 1‑800‑267‑9675, or complete an online complaint form.
Background
L-Dopa, also known as levodopa, is a prescription drug that is combined with other drug ingredients in anti-Parkinson's medications. It should be used only under the supervision of a health care professional. Levodopa may interact with drugs prescribed for high blood pressure, and should not be used by women who are pregnant, who plan to become pregnant or who are breastfeeding. It should also not be taken by people with narrow angle glaucoma; untreated heart, liver, kidney, lung or hormonal diseases; a history of melanoma; or those who should not take drugs such as isoproterenol, amphetamines or epinephrine. Side effects requiring medical attention include: uncontrollable movements of the face, eyelids, mouth, tongue, neck, arms, hands, or legs; severe or persistent nausea or vomiting; an irregular heartbeat or fluttering in the chest; feeling lightheaded when standing quickly; or unusual changes in mood or behaviour.
Yohimbine is a prescription drug and should be used only under the supervision of a health care professional. The use of drugs containing yohimbine (either as yohimbine hydrochloride or yohimbe bark extract) may result in serious adverse reactions, particularly in people with high blood pressure, or heart, kidney or liver disease. Side effects associated with yohimbine include increased blood pressure and heart rate, anxiety, dizziness, tremors, headache, nausea and sleep disorders. It should not be used by children, or pregnant or nursing women.
Synephrine and caffeine, when combined, may cause serious and possibly fatal adverse effects. Synephrine taken in combination with caffeine can cause side effects ranging from dizziness, tremors, headaches and irregularities in heart rate to seizures, psychosis, heart attacks and stroke.
What Health Canada is doing
Health Canada seized the products from the retail location and is taking action to prevent further distribution and sale of these products. Should additional retailers or distributors be identified, Health Canada will take appropriate action and inform Canadians.
For more information
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
To learn more about natural health products and other self-care products, visit Canada.ca/selfcare-products.
Également disponible en français
SOURCE Health Canada
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/January2017/27/c4783.html
Media Enquiries: Health Canada, (613) 957-2983; Public Enquiries: (613) 957-2991, 1-866 225-0709
Share this article